Latest COVID-19 research looks at vaccines’ efficacy, thrombocytopenia risk
Thrombosis with thrombocytopenia is a risk with the Johnson & Johnson (Janssen) vaccine, but not those using mRNA technology, one study found, while other research quantified the vaccines’ effectiveness over time. A trial found that monoclonal antibodies reduced progression from asymptomatic to symptomatic infection.